Figure 3. External beam RT synergizes with venetoclax to lengthen survival of mice bearing B-NHL xenografts.

Mice implanted with subcutaneous xenografts of A. Rec-1 (MCL) or B. SU-DHL-6 (GCB-DLBCL) were treated with either drug diluent only (control), 8 or 10 Gy external beam ¹³⁷Cs irradiation (RT), venetoclax (daily for 21 days), or RT plus venetoclax, when tumors were ~50mm³. Mouse survival was plotted on Kaplan-Meier curves. In both xenograft models, single-agent venetoclax (blue) did not significantly affect survival time (p > 0.2 compared with controls), but combining venetoclax with RT (green) extended mean survival times significantly beyond that provided by RT alone (purple) and cured at least 10% of mice (p < 0.007, combination groups > RT groups). Cure defined as survival to 120 days with no sign of relapse; synergy defined as survival of the combination group being greater than the additive survival benefits of each agent administered alone (Supplementary Table S1). N = 9–10 mice/group, additional statistics in text.